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A b s t r a c t
Background: Many studies have used creatinine kinase (CK), myocardial bound for CK (CK-MB), and cardiac troponin I
(cTnI) and T (cTnT) to evaluate myocardial cells injury after ablation. We applied measurements of the blood concentration
of cardio-specific biomarkers as surrogates for the injured cell mass.
Aim: To clarify which of the standard biomarkers are useful in the evaluation and quantification of lesions produced by
cryoballoon ablation (CBA) during pulmonary vein isolation.
Methods: The CBA was performed in 33 patients with atrial fibrillation. Blood samples were obtained before CBA and one,
six, and 24 h after CBA. We analysed CK, CK-MB and cTnI.
Results: A significant increase of all biomarkers was observed at each hour of collection as compared to the baseline mea-
surement. Maximum median peak levels occurred at 6 h. Pathological values of CK, CK-MB and cTnI were observed in 94%,
100% and 100% of patients, respectively. Both maximum CK and CK-MB values correlated with median temperature
(p < 0.05) reached during CBA. Additionally, CK-MB correlated with total cryo-time (p < 0.03).
Conclusions: The CK-MB is the best biochemical marker for the evaluation of myocardial injury after CBA. The cTnI can be
useful as an additional parameter of myocardial injury after CBA.
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INTRODUCTION
Different energy sources have been used to perform percuta-
neous transluminal catheter-based pulmonary vein isolation
(PVI) in patients with atrial fibrillation (AF). In recent years,
the cryoballoon (CB) technique has offered a new way of ac-
complishing PVI [1–3].
Several markers have been shown to be useful in the
diagnosis and evaluation of the size of myocardial injury after
an acute ischaemic episode. Tissue ablation creates immedia-
te myocardial necrosis. As a result, the release of myocardial
injury markers starts earlier than in ischaemic events [4–6]. Many
authors have tried to implement different biomarkers so as
to evaluate and quantify the size of effective ablation lesions
[4–12]. Both past and recently published studies have used
creatinine kinase (CK), myocardial bound for CK (CK-MB),
and cardiac troponins I (cTnI) and T (cTnT) to evaluate
myocardial cells injury after ablation [4–12].
We applied measurements of the blood concentration
of cardio-specific biomarkers, before and after ablation, as
surrogate parameters for the injured cell mass. The aim was
to clarify which of the standard biomarkers are useful in the
evaluation and quantification of lesions produced by CB (CBA).
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METHODS
Patients
The study population consisted of 33 consecutive patients
with symptomatic and drug refractory AF. The arrhythmia was
documented in at least two ECG, during three months prece-
ding an ablation procedure. The indications for ablation were
based on the relevant guidelines [13]. Patients with an eleva-
ted level of any of the investigated markers (CK, CK-MB, or
cTnI) at baseline were excluded from the study.
The procedural-related risk was fully explained and written
informed consent was obtained from all patients before the abla-
tion. The study was approved by the local ethics committee.
Ablation procedure
Left atrium was reached via double trans-septal approach.
We made selective angiography of all PVs. The CBA was per-
formed with a double-walled balloon (Arctic Front, Cryocath).
The degree of balloon occlusion was judged using a semi-
quantitative grading: from grade 4 = excellent (full retention
of contrast medium without visible outflow) to grade 1 = very
poor (immediate rapid outflow from the PV). We aimed for at
least one CBA with occlusion of grade 4 on every targeted
PV. Additional delivery of cryoenergy was applied after the
guidewire was placed in different branches of the PV with
early branching, which usually allowed for better contact of
the balloon at different sites of the PV antrum. One applica-
tion lasted 240–360 s per freeze and complete PVI was con-
firmed using a Lasso catheter (Biosense Webster). During CBA
of the antrum of the right-sided PVs, phrenic movement was
monitored by either continuous phrenic nerve stimulation
via a right atrial stimulation catheter or by continuous moni-
toring of spontaneous breathing. In all patients, PVI of all tar-
geted PVs was the therapeutic aim with the primary use of
a CB only. Each PV was estimated as successfully isolated if
no recurrence of conduction 20 min since the last CBA was
observed. This procedure has been described recently in de-
tail [3]. The number of applications, the lowest temperature
of each cryo-application, and the cumulative time of each
CBA application were also recorded.
Measurement of biomarkers
Blood samples were obtained during venous puncture before
ablation, and 1, 6 and 24 h after ablation. All serum samples
were analysed using standard laboratory kits (CL NAC, CKMBL
and STAT Troponin I Abbott®). The CK, CK-MB and cTnI cut-
-off values for diagnosis of myocardial infarction (MI) (167 U/L,
25 ng/mL, 0.01 ng/mL, respectively) were used.
Statistical analysis
Parametric data are expressed as median values and interquar-
tile range (i.e. 25–75). The median temperature was calculated
as the median of the lowest temperature reached for each cryo-
application performed in the patient. The Mann-Whitney
U-test was used to compare parametric data, and the c2 — for
non-parametric, data. The association of the biomarkers con-
centration with temperature and cryotime was tested using li-
near regression analysis. Multivariable regression analysis of each
biomarker was performed for adjusting on other clinical varia-
bles such as age, gender and left atrial size. A p value < 0.05
was considered statistically significant.
RESULTS
Patients and procedural characteristics
The studied sample consisted of 33 patients, 20 males, me-
dian age 55 (48–61) years. Thirty two patients had paroxy-
smal AF and one patient had persistent AF. Transthoracic
echocardiography was performed in all patients. Median value
of left ventricular ejection fraction was 62% (57–67). Median
diameters of short and long left atrium were 50 mm (48–55)
and 37 mm (35–40), respectively. None of the patients com-
plained of symptoms suggestive of ischaemia or had clinical
signs of a coronary ischaemic episode either before or during
the procedure. We did not find any changes of the ST-seg-
ment comparing ECG tracings before, during or after the pro-
cedure. The median number, time and temperature of appli-
cations were 14 (12–16), 74 min (64–86) and –40°C (–36 to
–45), respectively.
Biomarkers of myocardial injury
A significant increase of all biomarkers was observed at each
hour of collection compared to baseline measurement (Fig. 1).
Maximum median peak levels occurred at 6 h. Abnormal
values of CK, CK-MB and cTnI were observed in 94%, 100%
and 100% of patients, respectively.
Both maximum CK and CK-MB values correlated with
median temperature (p < 0.01, r = 0.39 and p < 0.05, r = 0.25,
respectively) reached during CBA (Fig. 2A, B). Additionally,
CK-MB correlated (Fig. 2C) with total cryo-time (p < 0.03,
r = 0.36). No correlation was found for cTnI.
DISCUSSION
We found that all studied biomarkers can be used for evalu-
ating myocardial injury after PVI performed with CBA. The
most useful biomarker for evaluating CBA  — induced myo-
cardial injury was CK-MB.
Cardiac biomarkers and low temperature
Previous reports have confirmed the in vitro stability of bio-
markers in low temperatures [14, 15], suggesting that analysis
of these markers is reliable after CBA. The lowest median tem-
perature in our group was –40°C. This temperature was low
enough to assume cell death, with rupture of the cell mem-
branes, due to ice crystal formation which starts much earlier
— at –10°C [16]. Buttery et al. [14] confirmed stability of CK-
-MB at –20°C. Woltersdorf et al. [15] froze serum samples at
–70°C: the intra-tissue temperature hardly reached during
CBA. They described no significant change in serum cTnT or
cTnI concentration. The CK activity was almost unchanged.
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A statistically significant decrease (2.6% of CK base-line acti-
vity, p < 0.01) was reached after 14 days of sample storage at
–70°C. Surprisingly, CK-MB concentration significantly (14.8%,
p < 0.01) increased in frozen samples. However, this storage
temperature was almost twice as low as that of the median
temperature reached in our patients.
Measurement of biomarkers
Only a single report has described myocardial injury biomarkers
after cryo-ablation [6]. It evaluated a small sub-group of ten pa-
tients after cryo-ablation of atrial flutter (AFL). Oswald et al. [6]
observed significantly higher peak values both for CK and
CK-MB at 6 h after cryo-ablation (356 U/L and 27 ng/mL,
respectively) than after radiofrequency ablation of AFL (84 U/L
and 19 ng/mL, respectively). These results accord with our
observations. The authors argued that higher levels of CK and
Figure 1. Comparison of the kinetics of creatine kinase (CK), myocardial bound for CK (CK-MB), and cardiac troponin I (cTnI).
Data are depicted as box plots with median values and interquartile range; MI — laboratory routine value of CK (167 U/L),
CK-MB (25 ng/mL) for detection of myocardial infarction (MI); *p < 0.05; **p < 0.005; ***p < 0.0001
Figure 2. Correlation of maximum values of creatine kinase (CK) (A) and myocardial bound for CK (CK-MB) (B) with median
temperature reached during cryoballoon ablation; C. Correlation of maximum values of myocardial bound for creatine kinase
(CK-MB) with total time of applications during cryoballoon ablation
CK-MB in the cryo-group reflect different lesions formation,
as compared to radiofrequency lesions. Bigger sheaths used
in the cryo-group led to higher CK values.
In our opinion, the significant rise in biomarkers levels
reflects effective myocardial death caused by CBA. Both CK
and CK-MB are quantitative parameters, and their peak valu-
es depend on the number of irreversibly destroyed myocar-
dial cells [17]. The CK is not as specific as CK-MB with re-
gards to myocardial cells injury. Therefore, we should focus
on CK-MB rather than on CK. A significant correlation be-
tween maximum values of CK-MB and total CBA time as well
as median temperature reflects the effectiveness of CBA in
annihilating myocardial cells. This observation is important in
clinical settings. The CBA parameter which can be directly
controlled by the operator is the time of application. After
setting the time of application as constancy, only lowering
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the temperature can further influence the effectiveness of
myocardial injury. The achieved temperature during CBA
depends on the quality of CB contact with myocardial issue.
The better the CB contact, the lower the temperature that
can be achieved as the blood flow between myocardial tissu-
es and balloon surface is stopped or at least significantly de-
creased. In such settings, CK-MB reflects mass of cells death.
Oswald et al. [6] also described a significant increase in
cTnT concentration, especially in the cryo-group, with the
cTnT highest levels 6 h after procedure. Although we measu-
red cTnI and not cTnT, we also observed the highest cTnI
values at 6 h blood collection from CBA patients. The values
of cTnI did not correlate with duration and temperature of
CBA, as early cardiac troponins are a qualitative marker of
myocardial injury [18]. Their peak value is related to injury
per se rather than reflecting mass of myocardial death.
We observed that the kinetics of myocardial injury mar-
kers showed earlier peak values then expected in the setting
of ischaemic heart disease, as described by previous authors
[19–21]. The ablation procedure results in immediate myo-
cardial necrosis, whereas ischaemic events develop more slow-
ly, even over hours. Peak concentrations of CK, CK-MB and
cTnI can be expected 12, 24 and 12–24 h after MI respecti-
vely [20, 22, 23]. In our study group, all the biomarkers cros-
sed their pathological values for detection of MI at the first
hour, and further increased to reach their maximal values at
the sixth hour. This could have practical application in the
differential diagnosis of chest pain or suspected acute MI after
CBA, especially in pacemaker-implanted patients with active
ventricular pacing in whom we can mostly judge on clinical
manifestation and biomarkers behaviour, but in whom we
receive only limited help from ECG tracings.
Limitations of the study
The detailed kinetics of biomarkers cannot be commented
on, because no blood collection was performed between 6 h
and 24 h. We cannot exclude the possibility that reaching
a temperature of –70oC and below could lead to an incre-
ased value of measured CK-MB concentration.
CONCLUSIONS
The CK-MB is the best biochemical marker for the evaluation
of myocardial injury after CBA. The cTn I can be useful as an
additional parameter of myocardial injury after CBA.
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Które ze standardowo dostępnych
biomarkerów są użyteczne w ocenie
uszkodzenia mięśnia sercowego
po krio−balonowej izolacji żył płucnych?
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S t r e s z c z e n i e
Wstęp: W dotychczas opublikowanych badaniach dotyczących oceny uszkodzenia mięśnia sercowego po zabiegach ablacji
oznaczano aktywność kinazy kreatynowej (CK), izoenzymu sercowego CK (CK-MB) i stężenie sercowych troponin I (cTnI)
oraz T (cTnT). Dokonano pomiarów koncentracji kardio-specyficznych biomarkerów jako odpowiednika masy uszkodzonych
komórek mięśnia sercowego.
Cel: Celem pracy było wyjaśnienie, który ze standardowo dostępnych biomarkerów jest użyteczny w ocenie uszkodzenia
komórek mięśnia sercowego po krio-balonowej izolacji żył płucnych (CBA).
Metody: U 33 pacjentów z migotaniem przedsionków wykonano CBA. Próbki krwi pobrano przed CBA oraz w 1., 6. oraz
24. godzinie po CBA. Analizie poddano CK, CK-MB i cTnI.
Wyniki: W próbkach pobranych po CBA zaobserwowano istotny wzrost koncentracji wszystkich badanych biomarkerów
w stosunku do poziomu wyjściowego. Maksymalny wzrost zanotowano w 6. godzinie; CK, CK-MB i cTnI osiągnęły wartości
patologiczne u, odpowiednio, 94%, 100% i 100% pacjentów. Maksymalne wartości CK i CK-MB korelowały (p < 0.05)
z medianą temperatury osiągniętej w czasie CBA.
Wnioski: Okazało się, że CK-MB jest najlepszym standardowym biomarkerem do oceny uszkodzenia mięśnia sercowego po
CBA. Sercowa troponina I może być użyteczna jako dodatkowy parametr oceny uszkodzenia po CBA.
Słowa kluczowe: biomarkery, uszkodzenie mięśnia sercowego, krio-balonowa ablacja, CK, CK-MB, troponina
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